The U.S. Food and Drug Administration approval on Monday of a new AIDS medicine is a first for the company Japan Tobacco Inc.2914. To +0.40%, who spent a quarter-century of research products with no product of his laboratory permit large U.S. market.
The FDA approved pill combination with AIDS that will be sold in the U.S. by Gilead Sciences, Inc. under the trade name Stribild, Jennifer Corbett reports Dooren.Produkt combines Gilead four different medications, one of which is a substance called elvitegravir. This was discovered by
Japan Tobacco and licensed to Gilead.
Separately Gilead seeks permission for elvitegravir as a standalone product.
According to the annual report of Gilead, issued in February 2012, it was $ 45 million in upfront and milestone payments in Japan Tobacco as Stribild progressing toward approval FDA, and will pay an undisclosed royalty rate on sales of products containing elvitegravir. Some analysts say,
Stribild sales could reach $ 3 billion a year by 2020.
Japan Tobacco is closer to FDA approval several times. He found the drug to enhance the body HDL, or “good” cholesterol, and licensed its Roche Holding AG. But after more than a decade of human trials in thousands of patients, Roche concluded earlier this year that the drug was not effective enough.
In the U.S. and Europe, pharmaceutical research, as a rule, in the province of specialized companies. Japan has given the world gout drug found textile manufacturer, cholesterol drug from fashion and diversified Electronics Company, and now, a cure for one of the major disasters in the world from the cigarette manufacturer. Specialists in drug say a few fields so unpredictable, and the list seems to offer enough evidence.